Abstract
Aim: The aim of our study is to assess the improvement of insulin resistance and other metabolic parameters in type 2 diabetic patients treated with glimepiride (GP) compared to glibenclamide (GB). Materials and methods: This single-blind, prospective study included 40 type 2 DM patients (age 55.43±8.3years, duration of diabetes 3.7±3.3years) without cardiovascular disease, which were randomly assigned to keep the original GB (n=20) therapy or switch to GP (n=20). Except anthropometric parameters, the following laboratory parameters were evaluated after 24weeks of treatment: fasting venous plasma glucose, lipid profile, HbA1C, insulin, adiponectin and hs-CRP.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
